Trial reportDrug design, development and therapy2025
Pyrotinib Plus Trastuzumab as an Effective Later-Line Therapeutic Strategy for HER2-Positive Metastatic Colorectal Cancer: Results from a Phase II Study.
Trial report in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Dual human epidermal growth factor receptor 2 (HER2) blockade demonstrates promising yet limited clinical activity in HER2-positive metastatic colorectal cancer (mCRC). This study was initiated to evaluate the novel combination of trastuzumab (anti-HER2 monoclonal antibody) and pyrotinib (a pan-HER tyrosine kinase inhibitor) in this molecularly defined population. Methods: This exploratory single-arm phase II trial enrolled HER2-positive mCRC patients refractory to standard first- and second-line therapies. Participants received intravenous trastuzumab (8 mg/kg loading dose on cycle 1 day 1, then 6 mg/kg every 3 weeks) plus oral pyrotinib 400 mg once daily in 21-day cycles. The primary endpoint was objective response rate (ORR). Results: Between December 1, 2019, and March 31, 2025, 20 patients were enrolled, with 17 evaluable for efficacy. The objective response rate (ORR) was 23.5% (4 partial responses), and the disease control rate (DCR) reached 88.2%. Median progression-free survival (PFS) was 6.2 months (95% CI, 0.42-11.98), and median overall survival (OS) was 21.1 months (95% CI, 15.84-26.36). Responses occurred exclusively in RAS/BRAF wild-type patients (ORR 28.6%; DCR 92.9%), who showed significantly longer median PFS (8.5 vs 2.6 months; HR 0.32; P=0.008) and OS (22.6 vs 4.9 months; P=0.022) versus KRAS-mutant counterparts. Treatment-related adverse events (TRAEs) included diarrhea (75%), fatigue (40%), and nausea (35%). Diarrhea accounted for all grade 3 TRAEs (30%). No grade ≥4 TRAEs were observed. Conclusion: Pyrotinib plus trastuzumab demonstrates clinically meaningful efficacy and a manageable safety profile in heavily pretreated HER2-positive metastatic colorectal cancer. These findings support advancing this regimen as a potential alternative in refractory HER2-positive mCRC, particularly in the RAS/BRAF wild-type subgroup.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.